ArriVent BioPharma, Inc. Reports 2025 Annual Meeting Results

Strategic Insights -

ArriVent BioPharma, Inc. held its 2025 annual meeting of stockholders on June 18, 2025, via live audio webcast. A quorum of 73.89% of eligible shares was present, with 25,159,248 shares represented. The stockholders elected two new directors, Zhengbin (Bing) Yao, Ph.D., and Kristine Peterson, to the Company's board of directors. Additionally, they ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Takeaways:

  • The 2025 annual meeting of stockholders for ArriVent BioPharma, Inc. was held on June 18, 2025, via live audio webcast.
  • A quorum of 73.89% of eligible shares was present, with 25,159,248 shares represented.
  • Stockholders elected Zhengbin (Bing) Yao, Ph.D., and Kristine Peterson to the Company's board of directors for a term of three years.
  • Kristine Peterson received 21,932,842 "for" votes, while Zhengbin (Bing) Yao, Ph.D., received 22,116,332 "for" votes.
  • Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
  • A total of 242 shares were voted against the auditor ratification, with 167,537 shares abstaining.
  • The number of broker non-votes for the auditor ratification was 0.

Statistics:

  • 34,045,193 shares of common stock were issued and outstanding and eligible to vote as of April 21, 2025.
  • 73.89% (25,159,248 shares) of eligible shares were present at the meeting or represented by proxy.
  • 22,116,332 votes were cast in favor of Zhengbin (Bing) Yao, Ph.D., while 442,833 votes were withheld.
  • 21,932,842 votes were cast in favor of Kristine Peterson, while 626,323 votes were withheld.
  • 242 shares were voted against the auditor ratification, with 167,537 shares abstaining.

Sources:

  • SEC.gov - Form 8-K
  • ArriVent BioPharma, Inc. - Definitive Proxy Statement on Schedule 14A
  • PricewaterhouseCoopers LLP